Analysts: Actavis-Allergan deal could create a marketing superpower

Valeant's ($VRX) been pursing Allergan ($AGN) for months now, but the California-based drugmaker may soon have another bid, too. Actavis ($ACT) is reportedly preparing to take its second stab at an Allergan deal, which could give Allergan some options. While the two potential transactions look comparable to Leerink Partners analysts Jason Gerberry and Seamus Fernandez from an accretion standpoint, the pair sees "less risk to Allergan brands suffering through the consolidation process" if Allergan combines with Actavis. Such a move "would unite two of the best marketing organizations in pharma," they wrote in a Wednesday note to shareholders. More

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.